JP2025528835A5 - - Google Patents

Info

Publication number
JP2025528835A5
JP2025528835A5 JP2025508673A JP2025508673A JP2025528835A5 JP 2025528835 A5 JP2025528835 A5 JP 2025528835A5 JP 2025508673 A JP2025508673 A JP 2025508673A JP 2025508673 A JP2025508673 A JP 2025508673A JP 2025528835 A5 JP2025528835 A5 JP 2025528835A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
cdr2
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025508673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025528835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/030268 external-priority patent/WO2024039672A2/en
Publication of JP2025528835A publication Critical patent/JP2025528835A/ja
Publication of JP2025528835A5 publication Critical patent/JP2025528835A5/ja
Pending legal-status Critical Current

Links

JP2025508673A 2022-08-15 2023-08-15 Mslnに対する抗体及びその使用方法 Pending JP2025528835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263398082P 2022-08-15 2022-08-15
US63/398,082 2022-08-15
PCT/US2023/030268 WO2024039672A2 (en) 2022-08-15 2023-08-15 Antibodies against msln and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025528835A JP2025528835A (ja) 2025-09-02
JP2025528835A5 true JP2025528835A5 (https=) 2025-11-04

Family

ID=87974270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025508673A Pending JP2025528835A (ja) 2022-08-15 2023-08-15 Mslnに対する抗体及びその使用方法

Country Status (7)

Country Link
EP (1) EP4573118A2 (https=)
JP (1) JP2025528835A (https=)
KR (1) KR20250108093A (https=)
CN (1) CN119855829A (https=)
AU (1) AU2023324669A1 (https=)
CA (1) CA3263672A1 (https=)
WO (1) WO2024039672A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025255291A1 (en) * 2024-06-07 2025-12-11 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting mesothelin and use thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
CN109071667A (zh) 2016-03-08 2018-12-21 马弗里克治疗公司 可诱导性结合蛋白和使用方法
CN120795163A (zh) 2016-10-14 2025-10-17 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台
EP3576793A4 (en) 2017-02-06 2021-03-31 Dana Farber Cancer Institute, Inc. COMPOSITIONS AND PROCEDURES FOR ENHANCING ANTIBODY-MEDIATED RECEPTOR SIGNALING
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN111315773A (zh) 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
US20210070860A1 (en) 2018-03-21 2021-03-11 Dana-Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules

Similar Documents

Publication Publication Date Title
JP7551693B2 (ja) NKp46結合タンパク質の可変領域
JP7550591B2 (ja) 多重特異的NKp46結合タンパク質
US20220135676A1 (en) Multispecific antigen binding proteins
JP7809680B2 (ja) 癌処置のための多重特異性結合タンパク質
JP6840682B2 (ja) 多重特異的抗原結合タンパク質
JP6971153B2 (ja) 多重特異的nkエンゲイジャータンパク質
CN107428830B (zh) 单体fc结构域
US20220226469A1 (en) Therapeutic sirp-alpha antibodies
AU2020200981A1 (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
JP2020536543A (ja) 抗cd38抗体および使用方法
CA3139508A1 (en) Materials and methods for modulating t cell mediated immunity
CN116745317B (zh) 抗tigit抗体及其用途
AU2021214622B2 (en) Means and method for modulating immune cell engaging effects.
JP2025528835A5 (https=)
KR20240036142A (ko) 3특이성 및/또는 3가 결합 단백질
US20250011422A1 (en) Siglec-6 antibodies, derivative compounds and related uses
WO2024094151A1 (en) Multi-specific antibody and medical use thereof
AU2026202063A1 (en) Means and method for modulating immune cell engaging effects.
TW202544039A (zh) 對cd47和pdl1具有特異性的多特異性抗體、編碼其之核酸、包含其之醫藥組合物、對應其之抗體結合域、包含對應其之抗體結合域之抗體及包含編碼其之核酸的宿主細胞
Kiprijanov Bispecific antibodies and immune therapy targeting